x
- Industry: Pharma & Lifesciences
- Study Type: Severe Eosinophilic Asthma (SEA) Study
- Client: A leading Research & Consultancy Firm
Background & Key Objectives
- The purpose of the study was to learn about physicians’ approach of diagnosing Severe Eosinophilic Asthma (SEA) and inclusion of biologics in the treatment plan.
- To identify patient eligibility on different biologics as per their clinical/baseline factors Concept
Methodology & Approach
- A nationally representative probability sample of office- and hospital-based Pulmonologists & Allergologists that diagnose and treat patients
- Length of Interview of the quantitative/qualitative survey: 45 minutes
- Target geography: USA, UK, Germany and Eastern Europe
- The surveys consisted of questions divided into different sections:
- Length of Interview of the quantitative survey: 30 minutes
- Patient journey
- Biomarker testing in SEA and their current utility (key biomarkers, % spilt of diagnosis referrals, IgE level in SEA diagnosis and the importance of eosinophil's in treatment regime)
- Patient profiles on each biologics
- Concept testing of a new Biologic in development
Our Solution
- Concept testing allowed the client to get the initial feedback of their under-development biologics targeted for SEA patients from the physicians (Pulmonologists & Allergologists).
- Overall and market-wise sub-split of early and late adopters of Biologics in the SEA.
- Trade-off features of the under development drug
- Intent to Prescribe
- Price Sensitivity Analysis